Page 88 - 80_01

Jorge
Enrique
Machado-­-Alba

4.
Greenhalgh
J,
Bagust
A,
Boland
A,
Blundell
M,
Oyee
J,
Beale
S,
et
al.
Rituximab
for
the
First-­-
Line
Maintenance
Treatment
of
Follicular
Non-­-Hodgkin's
Lymphoma
:
A
NICE
Single

Technology
Appraisal.
Pharmacoeconomics
31(5),
403-­-13
(2013).

5.
Niyazi
M,
Maihoefer
C,
Krause
M,
Rödel
C,
Budach
W,
Belka
C.
Radiotherapy
and
"new"

drugs-­-new
side
effects?
Radiat
Oncol
6,
177
(2011).

6.
Yan
L.
Molecular
targeted
agents-­--­-where
we
are
and
where
we
are
going.
Chin
J
Cancer

32(5),
225-­-32
(2013).

7.
American
Pharmacists
Associaton.
Drug
Information
Handbook.
21st
Edition.
Lexicomp

2012

8.
Tak
P,
Kalden
J.
Advances
in
rheumatology:
new
targeted
therapeutics.
Arthritis
Res
Ther

13(Suppl
1),
S5
(2011).

9.
Dyer
MJ.
Safety
and
efficacy
of
ofatumumab
in
patients
with
fludarabine
and
alemtuzumab

refractory
chronic
lymphocytic
leukaemia.
Ther
Adv
Hematol
3(4),
199-­-207
(2012).

10.
Wu
M,
Akinleye
A,
Zhu
X.
Novel
agents
for
chronic
lymphocytic
leukemia.
J
Hematol
Oncol

6,
36
(2013).

11.
Warner
JL,
Arnason
JE.
Alemtuzumab
use
in
relapsed
and
refractory
chronic
lymphocytic

leukemia:
a
history
and
discussion
of
future
rational
use.
Ther
Adv
Hematol
3(6),
375-­-89

(2012).

12.
Kousin-­-Ezewu
O,
Coles
A.
Alemtuzumab
in
multiple
sclerosis:
latest
evidence
and
clinical

prospects.
Ther
Adv
Chronic
Dis
4(3),
97-­-103
(2013).

13.
Feldmann
G,
Brossart
P,
Zipfel
M,
von
Lilienfeld-­-Toal
M.
Mixed
response
to
ipilimumab
in
a

melanoma
patient
with
brain
metastases:
case
report
and
review
of
the
literature.
Case

Rep
Oncol
6(1),
229-­-35
(2013).

14.
Wolchok
JD,
Kluger
H,
Callahan
MK,
Postow
MA,
Rizvi
NA,
Lesokhin
AM,
et
al.
Nivolumab

plus
Ipilimumab
in
Advanced
Melanoma.
N
Engl
J
Med
369(2),
122-­-33
(2013).

15.
Chiche
L,
Jourde
N,
Thomas
G,
Bardin
N,
Bornet
C,
Darque
A,
et
al.
New
treatment
options

for
lupus
-­-
a
focus
on
belimumab.
Ther
Clin
Risk
Manag
8,
33-­-43
(2012).

16.
Kim
SS,
Kirou
KA,
Erkan
D.
Belimumab
in
systemic
lupus
erythematosus:
an
update
for

clinicians.
Ther
Adv
Chronic
Dis
3(1),
11-­-23
(2012).

17.
Hamid
O,
Robert
C,
Daud
A,
Hodi
FS,
Hwu
WJ,
Kefford
R,
et
al.
Safety
and
Tumor
Responses

with
Lambrolizumab
(Anti-­-PD-­-1)
in
Melanoma.
N
Engl
J
Med
369(2),
134-­-44
(2013).

18.
Beck
A,
Reichert
JM.
Marketing
approval
of
mogamulizumab:
a
triumph
for
glyco-­-
engineering.
MAbs
4(4),
419-­-25
(2012).

19.
Tobinai
K,
Takahashi
T,
Akinaga
S.
Targeting
chemokine
receptor
CCR4
in
adult
T-­-cell

leukemia-­-lymphoma
and
other
T-­-cell
lymphomas.
Curr
Hematol
Malig
Rep
7(3),
235-­-40

(2012).

20.
Cooper
KL,
Madan
J,
Whyte
S,
Stevenson
MD,
Akehurst
RL.
Granulocyte
colony-­-stimulating

factors
for
febrile
neutropenia
prophylaxis
following
chemotherapy:
systematic
review

and
meta-­-analysis.
BMC
Cancer
11,
404
(2011).

21.
Barosi
G,
Bosi
A,
Abbracchio
MP,
Danesi
R,
Genazzani
A,
Corradini
P,
et
al.
Key
concepts
and

critical
issues
on
epoetin
and
filgrastim
biosimilars.
A
position
paper
from
the
Italian

Society
of
Hematology,
Italian
Society
of
Experimental
Hematology,
and
Italian
Group
for

Bone
Marrow
Transplantation.
Haematologica
96(7),
937-­-42
(2011).

22.
Agarwal
R,
Abidi
MH.
Successful
autologous
stem
cell
collection
with
filgrastim
and

plerixafor
after
long-­-term
lenalidomide
therapy
for
multiple
myeloma.
Hematol
Rep
4(4),

e26
(2012).

23.
Arora
S,
Bhargava
A,
Jasnosz
K,
Clark
B.
Relapsing
acute
kidney
injury
associated
with

pegfilgrastim.
Case
Rep
Nephrol
Urol
2(2),
165-­-71
(2012).

24.
Cesaro
S,
Nesi
F,
Tridello
G,
Abate
M,
Panizzolo
IS,
Balter
R,
et
al.
A
randomized,
non-­-
inferiority
study
comparing
efficacy
and
safety
of
a
single
dose
of
pegfilgrastim
versus

daily
filgrastim
in
pediatric
patients
after
autologous
peripheral
blood
stem
cell

transplant.
PLoS
One
8(1),
e53252
(2013).

25.
Jawad
M,
Yu
N,
Seedhouse
C,
Tandon
K,
Russell
NH,
Pallis
M.
Targeting
of
CD34+CD38-­-
cells

using
Gemtuzumab
ozogamicin
(Mylotarg)
in
combination
with
tipifarnib
(Zarnestra)
in

Acute
Myeloid
Leukaemia.
BMC
Cancer
12,
431
(2012).

26.
Zinzani
PL,
Viviani
S,
Anastasia
A,
Vitolo
U,
Luminari
S,
Zaja
F,
et
al.
Brentuximab
vedotin
in

relapsed/refractory
Hodgkin's
lymphoma:
Italian
experience
and
results
of
the
use
in
the

daily
clinic
outside
clinical
trials.
Haematologica
98(8),
1232-­-6
(2013).

86